Announcements Trials

Browse Landscape

Phase

Phase NA 7 Phase 3 7 Phase 2 7 Phase 4 2 Phase 1 2 Phase EARLY_PHASE1 1 Phase 2/3 1 Phase 1/2 1

Status

Unknown 4 Withdrawn 1 Terminated 1 Recruiting 1 Not yet recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 1

Interventions

pembrolizumab 109 Cyclophosphamide 89 fludarabine 70 Carboplatin 57 Injections 56 Bevacizumab 49 Specimen Handling 43 Gemcitabine 41 Magnetic Resonance Spectroscopy 40 Paclitaxel 39 Nivolumab 38 venetoclax 36 Dexamethasone 35 Cisplatin 34 Biopsy 34 Temozolomide 31 Docetaxel 29 atezolizumab 27 Capecitabine 27 Oxaliplatin 26 Fluorouracil 26 Pemetrexed 24 Irinotecan 24 Azacitidine 24 abemaciclib 23 toripalimab 22 Fulvestrant 22 fludarabine phosphate 21 Rituximab 21 Leucovorin 19

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Recruiting × Saline Solution × Clear all

NCT06888921 2026-04-01

MAIA-ovarian

Compugen Ltd

Phase 1/2 Recruiting

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡